Etracker Debug:
	et_pagename = "Archives of Industrial Hygiene and Toxicology|aiht|C|[EN]"
	
        
Jump to ContentJump to Main Navigation

Archives of Industrial Hygiene and Toxicology

The Journal of Institute for Medical Research and Occupational Health

4 Issues per year

IMPACT FACTOR increased in 2013: 0.727
5-year IMPACT FACTOR: 0.980

Open Access
VolumeIssuePage

Issues

Open Access

Treatment of Osteoporosis

Petra Šimić1 / Zlatko Giljević1 / Velimir Šimunić1 / Slobodan Vukičević1 / Mirko Koršić1

Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska1

Klinika za internu medicinu Kliničkog bolničkog centra Zagreb, Zagreb, Hrvatska2

Klinika za ženske bolesti i porode Kliničkog bolničkog centra Zagreb, Zagreb, Hrvatska3

This content is open access.

Citation Information: Archives of Industrial Hygiene and Toxicology. Volume 58, Issue 1, Pages 55–71, ISSN (Print) 0004-1254, DOI: 10.2478/v10004-007-0009-3, March 2007

Publication History

Published Online:
2007-03-28

Liječenje Osteoporoze

Osteoporoza je jedna od najčešćih metaboličkih bolesti i zahvaća 8 % do 10 % stanovništva. Budući da je prijelom najteža posljedica osteoporoze, vrlo je važno otkriti bolesnike koji imaju rizik nastanka prijeloma, dati im farmakološku terapiju i savjetovati im promjenu načina života. Nekoliko je lijekova pokazalo sposobnost smanjenja broja prijeloma kralježnice i/ili perifernog skeleta u bolesnika s osteoporozom. Antiresorptivni su lijekovi temelj terapije, ali su i anabolički lijekovi odnedavno proširili mogućnosti liječenja. Antiresorptivni lijekovi, estrogeni, selektivni modulatori estrogenskih receptora, bisfosfonati i kalcitonin, djeluju tako da smanjuju koštanu pregradnju. Paratireoidni hormon potiče novo stvaranje kosti popravljajući arhitekturu i gustoću kosti. Stroncijev ranelat smanjuje rizik osteoporotičnih prijeloma djelujući na oboje - smanjenje razgradnje i povećanje izgradnje kosti. Druga potencijalna liječenja osteoporoze također su opisana u ovome članku.

Treatment of Osteoporosis

Osteoporosis is among the most frequent metabolic diseases affecting 8 % to 10 % of the population. Since the most disturbing outcome of osteoporosis is a fracture, it is important to identify patients at risk and intervene with pharmacologic therapies and lifestyle changes. Several drugs have shown their ability to reduce vertebral and/or peripheral fractures in patients with osteoporosis. Antiresorptive agents are a basis of therapy, but anabolic drugs have recently widened therapeutic options. Antiresorptive medications, estrogens, selective estrogen receptor modulators, bisphosphonates and calcitonins, work by reducing the rates of bone remodeling. Parathyroid hormone stimulates new bone formation, repairing architectural defects and improving bone density. Strontium ranelate reduces the risk for osteoporotic fractures by both inhibiting bone resorption and increasing bone formation. Other potential therapies for osteoporosis are also reviewed in this article.

Keywords: bisphoshonates; estrogens; parathyroid hormone; selective estrogen receptor modulators; strontium ranelate

  • Simonelli C, Weiss TW, Morancey J, Swanson L, Chen YT. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 2005;21:1069-74. [CrossRef]

  • Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen lossmediation by interleukin-6. Science 1992;257:88-91.

  • Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997;99:1699-703.

  • Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991;88:6613-7.

  • Pennisi E. Drugs' link to genes reveals estrogen's many sides. Science 1996;273:1171.

  • Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30. [PubMed] [CrossRef]

  • Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New Engl J Med 2003;349: 523-34.

  • Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006;21:765-71. [CrossRef]

  • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.

  • Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.

  • Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life. New Engl J Med 2003;348:1839-54.

  • Black LJ, Sato M, Rowley ER. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9. [CrossRef]

  • Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med 1997;337:1641-7.

  • Sambrook P. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Best Pract Res Clin Rheumatol 2005;19:975-81. [CrossRef] [PubMed]

  • Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol raloxifene. Science 1996;273:1222-5.

  • Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7.

  • Barrett-Connor E, Mosca L, Collins P i sur. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med 2006;355:125-37.

  • Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 2006;7:2301-7. [CrossRef] [PubMed]

  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud Ke, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;281:2189-97.

  • Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. (CORE Investigators): Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61. [CrossRef]

  • Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990;322:1265-71.

  • Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40. [PubMed]

  • Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vananen HK, Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol 2002;61:1255-62.

  • Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.

  • Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9. [CrossRef]

  • van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.

  • Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7. [PubMed] [CrossRef]

  • Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2):S66-80. [CrossRef]

  • Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006;22:919-28. [CrossRef] [PubMed]

  • Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61. [CrossRef]

  • Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189-99.

  • Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. New Engl J Med 1998;338:485-92.

  • Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503-11.

  • Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;16:753-61. [CrossRef]

  • de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. New Engl J Med 2006;355:675-84.

  • Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebocontrolled trial. J Clin Endocrinol Metab 2000;85:1895-900. [CrossRef]

  • Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.

  • Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.

  • Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91. [PubMed] [CrossRef]

  • Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study. Bone 1996;19:527-33. [CrossRef]

  • Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871-8. [CrossRef]

  • Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307.

  • Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22.

  • Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003;32:273-84. [CrossRef] [PubMed]

  • Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-24. [PubMed] [CrossRef]

  • Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Des 2003;9:2659-76. [CrossRef] [PubMed]

  • Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 2007;26:44-9.

  • Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.

  • Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002;30:71-4.

  • Miyauchi A, Notoya K, Taketomi S. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 1996;137:3544-50.

  • Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8.

  • Darby AJ, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981;33:199-204. [PubMed] [CrossRef]

  • Parsons JA, Potts JT Jr. Physiology and chemistry of parathyroid hormone. Clin Endocrino Metab 1972;1:33-78.

  • Canalis E, Centrella M, Burch W, McCarthy TL. Insulinlike growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;8:60-5. [CrossRef]

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.

  • Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.

  • Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53. [CrossRef]

  • Lau KH, Farley JR, Freeman TK, Baylink DJ. A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase. Metabolism 1989;38:858-68.

  • Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New Engl J Med 2003;349:1216-26.

  • Ettinger B, San Martin JA, Crans GG, Pavo I 2004 Differential effects of teriparatide after treatment with raloxifene or alendronate. J Bone Miner Res19:745-51. [PubMed]

  • Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051-5. [PubMed] [CrossRef]

  • Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-15.

  • Whitfield JF. The bone growth-stimulating PTH and osteosarcoma. Medscape Womens Health 2001;6:7. [PubMed]

  • Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983;222:330-2.

  • Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New Engl J Med 1990;322:802-9.

  • Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991;1:155-61.

  • Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med. 2004;350:459-68.

  • Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11:1302-11.

  • Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-29. [PubMed] [CrossRef]

  • Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906-11. [PubMed] [CrossRef]

  • Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y. An uncoupling agent containin strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;9:607-15.

  • Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporosis Int 2003;14(Suppl 3):S19-24.

  • Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22. [CrossRef] [PubMed]

  • Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:206-6.

  • Quarles LD. Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling? J Bone Miner Res 1997;12:1971-4. [CrossRef]

  • Baron R. Biology of the osteoclast. U: Mundy GR, Martin TJ, urednici. Physiology and Pharmacology of Bone. Handbook of Experimental Pharmacology; Berlin: Springer-Verlag; 1993. str. 111-47.

  • Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-4.

  • Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H. Impairment of macrophage colonystimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res 1990;5:781-9.

  • Kodama H, Yamasaki A, Nose M, Niida S, Ohgame Y, Abe M, Kumegawa M, Suda T. Congenital osteoclast deficiency in osteopetrotic op/op mice is cured by injections of macrophage colony stimulating factor. J Exp Med 1991;173:269-72.

  • Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702. [CrossRef]

  • Yoneda T, Lowe C, Lee CH, Gutierrez G, Niewolna M, Williams PJ, Izbicka E, Uehara Y, Mundy GR. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo.J Clin Invest 1993;91:2791-5. [CrossRef]

  • Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M. Inhibition of osteoclastic bone resorption in vivo by echistatin an "arginylglycyl-aspartyl" (RDG) containing peptide. Endocrinology 1993;132:1411-3.

  • Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL. A peptidomimetic antagonist of the αv β3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.J Clin Invest 1997;99:2284-92. [CrossRef]

  • Horton MA, Davies J. Perspectives-adhesion receptors in bone. J. Bone Miner Res 1989;4:803-8. [PubMed]

  • Vaes E. The action of parathyroid hormone on the excretion and synthesis of lysosomal enzymes and on the extracellular release of acid by bone cells. J Cell Biol 1968;39:676-97. [CrossRef] [PubMed]

  • Eilon G, Raisz LG. Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture. Endocrinology 1978;103:1969-75.

  • Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA. Proteolytic activity of human osteoclast cathepsin K-expression, purification, activation, and substrate identification. J Biol Chem 1996;271:12517-24.

  • Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.

  • Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.

  • Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of soluble RANK-IgG Fc (RANK.Fc) fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572-8.

  • Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.

  • Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993;90:4485-9.

  • Abu-Amer Y, Tondravi MM. NFkappaB and bone: the breaking point. Nat Med 1997;3:1189-90.

  • Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.

  • Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683-6. [CrossRef] [PubMed]

  • Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207. [CrossRef] [PubMed]

  • Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass indeks on bone mineral density in men and women: the Framingham Study. J Bone Miner Res 1993;8:567-73.

  • Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81. [PubMed] [CrossRef]

Comments (0)

Please log in or register to comment.